No Data
No Data
Allarity Therapeutics Presents Phase 2 Clinical Data From Ongoing Trial In Advanced Ovarian Cancer Patients At The 2025 Annual Meeting For The Society Of Gynecologic Oncology
Express News | Allarity Therapeutics: Consented, Without Admitting or Denying SEC's Findings, to Entry of Administrative Cease-and-Desist Order
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination With Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
Allarity Announces New Phase 2 Protocol For Stenoparib In Advanced Ovarian Cancer, To Focus On Dose Optimization And DRP Selection Criteria; Enrollment Targets Patients With Platinum-Resistant Disease; Study Aims To Enhance Understanding Of Wnt...
Express News | Allarity Therapeutics Inc - Patient Enrollment Expected to Begin in First Half of 2025